Genomic Vision SA announced plans to test the ability of its FiberVision molecular combing technology to detect novel breast cancer (BRCA) gene types associated with predisposition to breast and ovarian cancer. In collaboration with strategic partner Quest Diagnostics, Genomic Vision will look to find out to what extent molecular combing can identify BRCA gene variants that are omitted by other test methods. The trial, which will be conducted in both the US and France, is expected to begin this month and to be completed in the coming summer.

Under a partnership agreement with Genomic Vision, Quest Diagnostics has been granted exclusive rights to develop, validate and market in the United States, India and Mexico tests based on molecular combing in the fields of breast and ovarian cancer.